Effects of Dietary Polystyrene Microplastics on Anxiety- and Depression-like Behaviors
NCT06247579 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 15
Last updated 2024-08-22
Summary
The objective of this clinical trial is to explore the potential impact of dietary polystyrene microplastics on anxiety- and depression-like behaviors in resident physicians. Specifically, the study aims to address two key questions:
1. Can dietary polystyrene microplastics induce alterations in the human gut microbiome?
2. Can dietary polystyrene microplastics exacerbate anxiety- and depression-like behaviors?
Participants will be divided into two groups based on their habitual eating practices: The control group, consisting of resident physicians, will use non-disposable plastic tableware (NDPT) provided by hospital canteens for two months. In contrast, the exposure group, also comprising resident physicians, will use disposable plastic tableware (DPT) made of polystyrene, provided by the same hospital canteens, over the same period.
Conditions
- Depression, Anxiety
Interventions
- OTHER
-
Dietary polystyrene microplastics from disposable plastic tableware
Microplastic release from the daily use of disposable plastic materials (e.g., plastic boxes) when holding hot food or drink.
Sponsors & Collaborators
-
Northern Jiangsu People's Hospital
lead OTHER
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- BASIC_SCIENCE
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 20 Years
- Max Age
- 30 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2024-01-01
- Primary Completion
- 2024-04-25
- Completion
- 2024-05-01
Countries
- China
Study Locations
More Related Trials
-
Treatment of Overweight Induced by Antipsychotic Medication in Young People With Autism Spectrum Disorders (ASD)
NCT01825798 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluating The Effects Of Cimetidine On The Elimination Of PD 0332334 From The Body
NCT00800280 ·Status: TERMINATED ·Phase: PHASE1
-
Efficacy of Lifestyle Interventions and Metformin for the Treatment of Antipsychotic-Induced Weight Gain
NCT00451399 ·Status: COMPLETED ·Phase: PHASE4
-
Metformin Alleviates Abnormal Glucose Metabolism Induced by Statins in Schizophrenia Patients
NCT07045142 ·Status: RECRUITING ·Phase: PHASE3
-
Antipsychotics and Metabolic Syndrome
NCT00636753 ·Status: SUSPENDED
-
Chromium Piccolinate in the Prevention of Weight Gain Induced by Serotonergic Medications Initiated on Psychiatric Inpatient Units.
NCT00759993 ·Status: TERMINATED ·Phase: PHASE2
-
Multivitamin Impact on Micronutrient Status in GLP-1 Users: A Randomized Trial
NCT07234916 ·Status: ENROLLING_BY_INVITATION ·Phase: NA
-
Metformin for Treatment of Antipsychotic-induced Dyslipidemia
NCT01778244 ·Status: COMPLETED ·Phase: PHASE4
-
The Impact of the Mediterranean Diet on Anthropometric Indices, Lipid Profiles, Energy Metabolism Signaling Proteins and Inflammatory Cytokines in Psychiatric Patients With Metabolic Syndrome
NCT07164014 ·Status: COMPLETED ·Phase: NA
-
Reducing Antipsychotic-Induced Weight Gain in Children With Metformin
NCT01231074 ·Status: COMPLETED ·Phase: PHASE1
-
Metformin for Overweight & OBese ChILdren and Adolescents With BDS Treated With SGAs
NCT02515773 ·Status: COMPLETED ·Phase: PHASE4
-
To Demonstrate the Relative Bioavailability of Geneva and Basel (Anafranil) 25 mg Clomipramine Hydrochloride Capsules Under Fed and Fasted Conditions
NCT00913952 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy and Safety of Lisdexamfetamine Dimesylate in Adults With Chronic Fatigue Syndrome
NCT01071044 ·Status: COMPLETED ·Phase: PHASE4
-
Green Tea Extract for Obesity of Psychiatric Patients
NCT03548103 ·Status: COMPLETED ·Phase: NA
-
Effects of LDX on Cognitive Processes and Appetite
NCT04181957 ·Status: TERMINATED ·Phase: NA
-
The Effect of GLP-1 Receptor Activation on Central Reward and Satiety in Obesity and Diabetes
NCT01281228 ·Status: COMPLETED ·Phase: NA
-
The Therapeutic Effects of Topiramate and Metformin on Second Generation Antipsychotics-induced Obesity
NCT01384279 ·Status: COMPLETED ·Phase: NA
-
Effects of Hyperprolactinemia Induced by Antipsychotic Drugs on Bone Metabolism
NCT03675750 ·Status: UNKNOWN
-
Antipsychotic Medicine and Metabolic Syndrome
NCT00627757 ·Status: UNKNOWN
-
Beta-carotene and Oxidative Stress in Pediatric Second Generation Antipsychotic Use
NCT02363816 ·Status: WITHDRAWN
-
Metformin in Co-morbid Diabetes or Prediabetes and Serious Mental Illness
NCT02167620 ·Status: COMPLETED ·Phase: PHASE4
-
Changes in Metabolic Rate and Perceptual Indicators After Acute Ingestion of Paraxanthine
NCT05811923 ·Status: COMPLETED ·Phase: NA
-
Effect of Metabolic State on Anxiety in Human Subjects
NCT01322243 ·Status: TERMINATED ·Phase: NA
-
Reducing Weight and Diabetes Risk in an Underserved Population (STRIDE)
NCT00790517 ·Status: COMPLETED ·Phase: PHASE2
-
Effect of mCPP on Cognitive Control, Appetite, and Neural Responses
NCT03962829 ·Status: TERMINATED ·Phase: NA